DURECT Past Earnings Performance
Past criteria checks 0/6
DURECT's earnings have been declining at an average annual rate of -13.8%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 11.6% per year.
Key information
-13.8%
Earnings growth rate
-4.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -11.6% |
| Return on equity | -186.9% |
| Net Margin | -323.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How DURECT makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 9 | -28 | 14 | 0 |
| 30 Sep 23 | 9 | -37 | 16 | 0 |
| 30 Jun 23 | 19 | -36 | 16 | 0 |
| 31 Mar 23 | 19 | -36 | 16 | 0 |
| 31 Dec 22 | 19 | -35 | 16 | 0 |
| 30 Sep 22 | 23 | -32 | 16 | 0 |
| 30 Jun 22 | 13 | -39 | 15 | 0 |
| 31 Mar 22 | 14 | -37 | 15 | 0 |
| 31 Dec 21 | 14 | -36 | 14 | 0 |
| 30 Sep 21 | 9 | -38 | 13 | 0 |
| 30 Jun 21 | 9 | -37 | 14 | 0 |
| 31 Mar 21 | 31 | -14 | 14 | 0 |
| 31 Dec 20 | 30 | -14 | 14 | 0 |
| 30 Sep 20 | 34 | -11 | 14 | 0 |
| 30 Jun 20 | 43 | -3 | 14 | 0 |
| 31 Mar 20 | 23 | -24 | 14 | 0 |
| 31 Dec 19 | 25 | -21 | 14 | 0 |
| 30 Sep 19 | 23 | -24 | 14 | 0 |
| 30 Jun 19 | 20 | -24 | 13 | 0 |
| 31 Mar 19 | 19 | -24 | 13 | 0 |
| 31 Dec 18 | 15 | -25 | 12 | 0 |
| 30 Sep 18 | 34 | -10 | 12 | 0 |
| 30 Jun 18 | 35 | -1 | 12 | 0 |
| 31 Mar 18 | 36 | -4 | 13 | 0 |
| 31 Dec 17 | 37 | -4 | 13 | 0 |
| 30 Sep 17 | 21 | -21 | 13 | 0 |
| 30 Jun 17 | 16 | -36 | 13 | 0 |
| 31 Mar 17 | 15 | -35 | 12 | 0 |
| 31 Dec 16 | 14 | -35 | 12 | 0 |
| 30 Sep 16 | 16 | -32 | 12 | 0 |
| 30 Jun 16 | 17 | -29 | 12 | 0 |
| 31 Mar 16 | 18 | -26 | 12 | 0 |
| 31 Dec 15 | 19 | -23 | 12 | 0 |
| 30 Sep 15 | 18 | -23 | 12 | 0 |
| 30 Jun 15 | 18 | -23 | 12 | 0 |
| 31 Mar 15 | 18 | -23 | 12 | 0 |
| 31 Dec 14 | 19 | -22 | 12 | 0 |
| 30 Sep 14 | 19 | -21 | 13 | 0 |
| 30 Jun 14 | 18 | -20 | 13 | 0 |
| 31 Mar 14 | 17 | -20 | 13 | 0 |
| 31 Dec 13 | 15 | -21 | 13 | 0 |
| 30 Sep 13 | 14 | -22 | 12 | 0 |
| 30 Jun 13 | 15 | -21 | 12 | 0 |
Quality Earnings: DC8A is currently unprofitable.
Growing Profit Margin: DC8A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DC8A is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.
Accelerating Growth: Unable to compare DC8A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DC8A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.5%).
Return on Equity
High ROE: DC8A has a negative Return on Equity (-186.86%), as it is currently unprofitable.